Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash & Equivalents (2018 - 2025)

BioNexus Gene Lab's Cash & Equivalents history spans 8 years, with the latest figure at $2.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $2.4 million for Q4 2025, down 17.44% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (down 17.44% YoY), and the annual figure for FY2025 was $2.4 million, down 17.44%.
  • Cash & Equivalents for Q4 2025 was $2.4 million at BioNexus Gene Lab, up from $1.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $6.1 million in Q3 2023 to a low of $297084.0 in Q2 2023.
  • The 5-year median for Cash & Equivalents is $2.0 million (2022), against an average of $2.4 million.
  • The sharpest move saw Cash & Equivalents surged 1233.7% in 2024, then crashed 81.29% in 2025.
  • Year by year, Cash & Equivalents stood at $2.1 million in 2021, then decreased by 0.24% to $2.1 million in 2022, then soared by 113.21% to $4.5 million in 2023, then crashed by 36.1% to $2.9 million in 2024, then dropped by 17.44% to $2.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $2.4 million, $1.4 million, and $814179.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.